$42.00
(Market cap
$20,209 Mln
Recently Viewed
Clear AllMarket cap
$20,209 Mln
Revenue (TTM)
$2,459 Mln
P/E Ratio
--
P/B Ratio
7
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-882 Mln
ROE
-0.2 %
ROCE
-19.7 %
Industry P/E
--
EV/EBITDA
-11.9
Debt to Equity
0.3
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
97,675,800
CFO
$-6,659.54 Mln
EBITDA
$-7,912.40 Mln
Net Profit
$-7,811.45 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
BeiGene (BGNE)
| 22.7 | 24.6 | 4.4 | 40.0 | 2.1 | 7.3 | -- |
|
BSE Sensex*
| -8.3 | 4.2 | -5.6 | -2.4 | 9.2 | 10.1 | 11.6 |
|
S&P 100#
| 1.6 | 10.4 | 4.6 | 41.4 | 23.0 | 13.1 | 14.2 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
BeiGene (BGNE)
| 2.4 | -18.0 | -18.8 | 4.9 | 55.9 | 18.2 | 43.3 |
|
S&P 100
| 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 | -5.8 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
BeiGene (BGNE)
|
226.7 | 20,209.1 | 2,458.8 | -881.7 | -26.4 | -24.9 | -- | 7.0 |
| 793.2 | 53,060.7 | 4,164.2 | 1,296.0 | 9.5 | 20.2 | 43.3 | 7.2 | |
| 19.6 | 1,263.0 | 0.0 | -147.4 | -29,734.7 | -150.3 | -- | 7.5 | |
| 29.1 | 1,966.4 | 1,112.2 | 320.9 | -17.8 | 10.5 | 5.1 | 0.5 | |
| 27.7 | 17,527.2 | 3,722.9 | 963.8 | 40.1 | 4.5 | 18.5 | 3.0 | |
| 14.6 | 2,706.5 | 550.0 | 458.1 | -3.3 | 45.9 | 5.9 | 2.2 | |
| 15.8 | 2,154.2 | 17.2 | -102.1 | -363.1 | -19 | -- | 3.7 | |
| 17.1 | 1,224.6 | 403.3 | 22.8 | 3,081.6 | 9.1 | 433.5 | 4.4 | |
| 4.0 | 687.9 | 4.6 | -201.1 | -4,342.4 | -146.8 | -- | 5.7 | |
| 22.9 | 2,732.0 | 460.2 | -175.5 | -37.7 | -22.6 | -- | 3.8 |
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of... Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands. Read more
Co-Founder, Executive Chairman & CEO
Mr. John V. Oyler
Co-Founder, Executive Chairman & CEO
Mr. John V. Oyler
Headquarters
Camana Bay
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of BeiGene Ltd (BGNE) is $226.71 (NASDAQ) as of 29-Jan-2025 09:30 EDT. BeiGene Ltd (BGNE) has given a return of 2.11% in the last 3 years.
Since, TTM earnings of BeiGene Ltd (BGNE) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
The 52-week high and low of BeiGene Ltd (BGNE) are Rs -- and Rs -- as of 23-Apr-2026.
BeiGene Ltd (BGNE) has a market capitalisation of $ 20,209 Mln as on 29-Jan-2025. As per SEBI classification, it is a Large Cap company.
Before investing in BeiGene Ltd (BGNE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.